{"id":32501,"date":"2025-09-08T12:57:04","date_gmt":"2025-09-08T12:57:04","guid":{"rendered":"https:\/\/www.tabukpharmaceuticals.com\/?p=32501"},"modified":"2026-06-10T12:57:57","modified_gmt":"2026-06-10T12:57:57","slug":"tabuk-pharma-signs-exclusive-license-and-supply-agreement-with-hanmi-pharmaceutical-for-rolontis-eflapegrastim-in-saudi-arabia-and-mena","status":"publish","type":"post","link":"https:\/\/www.tabukpharmaceuticals.com\/ar\/tabuk-pharma-signs-exclusive-license-and-supply-agreement-with-hanmi-pharmaceutical-for-rolontis-eflapegrastim-in-saudi-arabia-and-mena\/","title":{"rendered":"Tabuk Pharma Signs Exclusive License and Supply Agreement with Hanmi Pharmaceutical for Rolontis\u00ae (Eflapegrastim) in Saudi Arabia and MENA"},"content":{"rendered":"<p>Tabuk Pharma and Hanmi Pharmaceutical have signed an exclusive license and supply agreement for Rolontis\u00ae (Eflapegrastim), an innovative biologic for the treatment of chemotherapy-induced neutropenia, across Saudi Arabia and the MENA region.<\/p>\n<p>This strategic collaboration underscores Tabuk Pharma\u2019s commitment to expanding access to advanced biologics and specialty medicines in alignment with Saudi Vision 2030, contributing to improved patient outcomes and the long-term advancement of regional healthcare.<\/p>\n<p>For more information, please visit the full announcement.<br \/>\nhttps:\/\/www.linkedin.com\/posts\/tabuk-pharmaceutical-mfg-co_tabuk-pharmaceuticals-x-hanmi-prl-eng-activity-7370794024003215360-P_qj\/<\/p>","protected":false},"excerpt":{"rendered":"<p>Tabuk Pharma and Hanmi Pharmaceutical have signed an exclusive license and supply agreement for Rolontis\u00ae (Eflapegrastim), an innovative biologic for the treatment of chemotherapy-induced neutropenia, across Saudi Arabia and the MENA region. This strategic collaboration underscores Tabuk Pharma\u2019s commitment to expanding&#8230;<\/p>","protected":false},"author":1,"featured_media":32502,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[61],"tags":[],"class_list":["post-32501","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-releases"],"_links":{"self":[{"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/posts\/32501","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/comments?post=32501"}],"version-history":[{"count":1,"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/posts\/32501\/revisions"}],"predecessor-version":[{"id":32503,"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/posts\/32501\/revisions\/32503"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/media\/32502"}],"wp:attachment":[{"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/media?parent=32501"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/categories?post=32501"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/tags?post=32501"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}